Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93.1M
-
Number of holders
-
232
-
Total 13F shares, excl. options
-
81.8M
-
Shares change
-
-1.54M
-
Total reported value, excl. options
-
$2.11B
-
Value change
-
-$23.7M
-
Put/Call ratio
-
0.73
-
Number of buys
-
105
-
Number of sells
-
-113
-
Price
-
$25.84
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q2 2017
286 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q2 2017.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 232 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.8M shares
of 93.1M outstanding shares and own 87.83% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (9.67M shares), BlackRock Inc. (9.45M shares), VANGUARD GROUP INC (6.31M shares), D. E. Shaw & Co., Inc. (4.78M shares), DIMENSIONAL FUND ADVISORS LP (3.43M shares), Consonance Capital Management LP (3.27M shares), STATE STREET CORP (3.11M shares), FRONTIER CAPITAL MANAGEMENT CO LLC (3.03M shares), Camber Capital Management LLC (3M shares), and THRIVENT FINANCIAL FOR LUTHERANS (2.74M shares).
This table shows the top 232 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.